Novavax | NVAX - Net Income


Novavax reported $-121.3M in Net Income for its fiscal quarter ending in September of 2024.





Net Income Change Date
Adma Biologics USD 36.43M 2.21M Sep/2025
Agenus USD -25.27M 20.59M Mar/2025
AstraZeneca USD 2.33B 207M Dec/2025
BioCryst Pharmaceuticals USD -88.88M 74.85M Dec/2024
Cassava Sciences USD -10.81M 33.41M Sep/2025
Geron USD -31.14M 12.72M Dec/2025
GlaxoSmithKline GBP 636M 1.38B Dec/2025
MannKind USD -15.95M 23.93M Dec/2025
Merck USD 2.96B 2.82B Dec/2025
Minerva Neurosciences USD 1.44M 21.07M Dec/2024
Moderna USD -200M 625M Sep/2025
Novartis USD 3.93B 113M Sep/2025
Novavax USD -121.3M 283.68M Sep/2024
Pfizer USD -1.65B 5.19B Dec/2025
Sanofi EUR -801M 3.6B Dec/2025
Sarepta Therapeutics USD -412.23M 232.28M Dec/2025
TG Therapeutics USD 23.04M 367.86M Dec/2025